Skip to main content
. Author manuscript; available in PMC: 2023 Nov 24.
Published in final edited form as: Gynecol Oncol. 2022 Sep 30;167(2):213–225. doi: 10.1016/j.ygyno.2022.09.019

FIGURE 1.

FIGURE 1.

Spider plot of tumor size change from baseline A. Cohort 1: Platinum resistant, BRCA-wildtype with ≥3 prior lines of therapy; B. Cohort 2: Platinum resistant, BRCA-wildtype with <3 prior lines of therapy; C. Cohort 3: Platinum resistant, BRCA-mutated with prior PARP inhibitor therapy; D. Cohort 4: Platinum refractory with any number of prior lines of therapy

Abbreviations: BOR, best overall response; CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.